Combination Therapy with iRGD-antiCD3 and PD-1 Blockade Enhances Antitumor Potency of Cord Blood-Derived T Cells

BACKGROUND: T cell-redirecting bispecific antibodies (BsAbs) are emerging as a potent cancer therapy that crosslinks tumor cells and T cells by simultaneously binding to tumor-associated antigen and CD3ε. However, immune inhibitory molecules can be remarkably upregulated after BsAbs treatment, leadi...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Onco Targets Ther
Päätekijät: Zhu, Mei, Wang, Hongmei, Zhou, Shujuan, Wei, Jia, Ding, Naiqing, Shao, Jie, Yu, Lixia, Feng, Zhenqing, Liu, Baorui
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Dove 2021
Aiheet:
Original Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7873023/
https://ncbi.nlm.nih.gov/pubmed/33574677
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S291086
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia